Literature DB >> 369298

A double-blind comparison of flupenthixol, nortriptyline and diazepam in neurotic depression.

D A Johnson.   

Abstract

A double-blind trial of flupenthixol, nortriptyline and diazepam in neurotic depression using flexible dose schedules suggested that each drug is an efficient treatment for this category of depression although the patterns of response and prevalence of side-effects varied. No differences reaching a level of significance could be shown on rating scales of depression or anxiety, but trends favoured flupenthixol. However, clinical evaluation suggested flupenthixol to be more effective than diazepam on mental state examination (P less than 0.05) and to have a greater overall therapeutic effect than nortriptyline (P less than 0.05). It also had fewer side-effects than nortriptyline (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 369298     DOI: 10.1111/j.1600-0447.1979.tb06940.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

1.  The use of benzodiazepines in depression.

Authors:  D A Johnson
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

2.  The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.

Authors:  S Kutcher; G Papatheodorou; S Reiter; D Gardner
Journal:  J Psychiatry Neurosci       Date:  1995-03       Impact factor: 6.186

Review 3.  A comparison of active drugs for the treatment of dysthymia.

Authors:  M Silva de Lima; M Hotopf
Journal:  Cochrane Database Syst Rev       Date:  2003

4.  The place of anxiety in depressive symptomatology.

Authors:  D Widlocher; Y Lecrubier; Y Le Goc
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

5.  Some considerations on the role of benzodiazepines in the treatment of depression.

Authors:  G B Cassano; L Conti
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.